Cumberland Pharmaceuticals (NASDAQ:CPIX) Receives New Coverage from Analysts at assumed coverage on shares of Cumberland Pharmaceuticals (NASDAQ:CPIXGet Rating) in a research note issued to investors on Tuesday. The firm set a “hold” rating on the specialty pharmaceutical company’s stock.

Cumberland Pharmaceuticals Trading Down 1.9 %

Shares of CPIX stock opened at $2.61 on Tuesday. Cumberland Pharmaceuticals has a 1 year low of $1.89 and a 1 year high of $3.81. The firm has a fifty day moving average price of $2.34 and a 200-day moving average price of $2.36. The company has a debt-to-equity ratio of 0.46, a current ratio of 1.94 and a quick ratio of 1.52. The company has a market cap of $38.27 million, a price-to-earnings ratio of -5.55 and a beta of 0.25.

Cumberland Pharmaceuticals (NASDAQ:CPIXGet Rating) last issued its quarterly earnings data on Tuesday, November 8th. The specialty pharmaceutical company reported $0.09 earnings per share (EPS) for the quarter. Cumberland Pharmaceuticals had a negative net margin of 16.93% and a negative return on equity of 1.86%. The firm had revenue of $11.41 million during the quarter.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Cumberland Pharmaceuticals stock. Acadian Asset Management LLC increased its position in Cumberland Pharmaceuticals Inc. (NASDAQ:CPIXGet Rating) by 27.8% in the 1st quarter, according to its most recent 13F filing with the SEC. The firm owned 188,243 shares of the specialty pharmaceutical company’s stock after buying an additional 40,949 shares during the period. Acadian Asset Management LLC owned about 1.27% of Cumberland Pharmaceuticals worth $529,000 at the end of the most recent quarter. Institutional investors and hedge funds own 16.69% of the company’s stock.

Cumberland Pharmaceuticals Company Profile

(Get Rating)

Cumberland Pharmaceuticals, Inc is a specialty pharmaceutical company, which engages in the acquisition, development, and commercialization of prescription products. Its product include Acetadote, Caldolor, Kristalose, Omeclamox, Vaprisol, Vibativ, and RediTrex. The company was founded by A. J. Kazimi on January 6, 1999 and is headquartered in Nashville, TN.

See Also

Receive News & Ratings for Cumberland Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cumberland Pharmaceuticals and related companies with's FREE daily email newsletter.